Phase 1 PNH Clinical Trials
6 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–6 of 6 trials
Recruiting
Phase 1Phase 2
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Paroxysmal Nocturnal Hemoglobinuria, PNH
ADARx Pharmaceuticals, Inc.50 enrolled4 locationsNCT05876312
Recruiting
Phase 1
A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants
Paroxysmal Nocturnal Hemoglobinuria, PNHComplement-mediated Kidney Disease
Shenzhen Kangzhe Biotechnology Co., Ltd.88 enrolled1 locationNCT07462780
Recruiting
Phase 1Phase 2
A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor
Paroxysmal Nocturnal Hemoglobinuria, PNHPersistent Anemia
Regeneron Pharmaceuticals24 enrolled7 locationsNCT07187401
Recruiting
Phase 1
A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)
PNH - Paroxysmal Nocturnal Hemoglobinuria
Shanghai Lanyi Therapeutics Co., Ltd.24 enrolled2 locationsNCT07256301
Recruiting
Phase 1
Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment
Paroxysmal Nocturnal Hemoglobinuria, PNH
Haisco Pharmaceutical Group Co., Ltd.24 enrolled1 locationNCT07152288
Completed
Phase 1
A randomised, double-blind, single-dose study to evaluate the pharmacokinetic, safety, tolerability, immunogenicity and pharmacodynamic profile of ISU305 compared to Soliris® (Eculizumab) in Healthy Male Volunteers
Atypical haemolytic uraemic syndrome (aHUS)Paroxysmal nocturnal haemoglobinuria (PNH)
ISU Abxis148 enrolled2 locationsACTRN12619000694112